text.skipToContent text.skipToNavigation

CAR-T Cells: Breakthroughs in Cancer and Auto-Immune Therapies

One of the most revolutionary cell therapies to transition from bench to bedside in the past decade is undoubtedly the development of chimeric antigen receptor (CAR)-T cells. Here, CAR-T cells have found a plethora of different applications. Firstly, by proving to be an effective treatment for certain blood cancers that were previously deemed incurable. Secondly, in holding promise for treating certain auto-immune diseases and solid tumours.

Lire la suite

CAR-T Cell Development – The Future of Fighting Cancer


CAR-T cells, genetically engineered and equipped with specific receptors to target and combat cancer cells, are primarily divided into two categories: autologous and allogenic CAR-T cells. Hereby, autologous CAR-T cells derive from the patient’s own white blood cells and are reintroduced after modification, whereas allogenic CAR-T cells are designed as off-the-shelf solutions for use in different patients. However, both approaches have their challenges. The manufacturing process for autologous CAR-T cells is complex and costly, as each patient’s cells must be individually processed. Allogeneic CAR-T cells, on the other hand, currently do not have the same safety profile, necessitating further research to address these issues.

Downloads

Brochure
PDF
Poster
PDF
Application Note
PDF
Application Note
PDF
Application Note
PDF
Resource Guide
PDF
Poster
PDF
Application Note
PDF
Application Note
PDT
White Paper
PDF